President Joe Biden’s campaign promise to reschedule marijuana from Schedule I to Schedule III has sent shockwaves through the stock market, potentially giving rise to a wave of stock rallies.
In an in-depth equity research report, senior analyst Pablo Zuanic of Zuanic & Associates delves into the profound effects of this possible reclassification on the cannabis stock market.
Factors That Will Influence the Market Impact
The report points out critical factors that will dictate the extent of this impact, such as the timing and manner of the announcement, the length of the comment period, and the content of the DEA memo.
Zuanic express concerns over the potential involvement of pharmaceutical and alcohol lobbies during the comment period and the varying reactions from both liberal and conservative factions concerning rescheduling. A swift decision before the election is deemed favorable for stocks.
Uncertainties And Regulatory Framework
The pending decision by the DEA could follow the conventional wisdom of moving marijuana to Schedule III, yet uncertainties loom regarding the DOJ’s final stance and the regulatory framework.
Zuanic raises questions about the possible paths the DEA may take, expressing doubt that the DEA may accept the ‘conventional wisdom’ narrative. He anticipates the DEA to propose a regulatory framework consistent with substances and drugs in Schedule III, creating potential challenges for the industry.
Feasibility of Fulfilling Biden’s Cannabis Promises
The report also scrutinizes the feasibility of Biden’s campaign promises related to decriminalization, medical cannabis legislation, and state autonomy on marijuana laws. It highlights the complexities of federal versus state jurisdiction and the legal intricacies of rescheduling versus descheduling, casting doubts on the straightforward implementation of these promises.
Zuanic’s analysis suggests progress toward fulfilling campaign promises, yet regulatory challenges complicate their full realization.
Investment Considerations and Strategy
The report advises investors to assess both growth potential and profitability, as well as debt leverage when evaluating cannabis stocks. It suggests a cautious approach to trading amidst this news flow, emphasizing the need for a nuanced approach to stock evaluation in the sector.
Zuanic advises considering valuation multiples within the broader context of potential growth, profitability, and debt leverage while emphasizing the need for a nuanced approach to stock evaluation in the sector.
The report ultimately concludes that a rescheduling or descheduling decision might not be enacted before the election, impacting the industry’s tax provisioning and payments.
Photo: AI-Generated Image.
